Evidence map›Paper›PMID 40427638›Full record

ArticleBiomolecules2025

Real-World Analysis of HRD Assay Variability in High-Grade Serous Ovarian Cancer: Impacts of BRCA1/2 Mutation Subtypes on HRD Assessment.

Giovanni Luca Scaglione, Valentina Lombardo, Maurizio Polano, Giuseppa Scandurra, Angela Pettinato, Corrado Giunta, Rosario Iemmolo, Paolo Scollo, Ettore D Capoluongo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giovanni Luca ScaglioneBioinformatics Unit, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.ORCID 0000-0001-5622-7843
Valentina LombardoDepartment of Medical Oncology, A.O.E. Cannizzaro, 95126 Catania, Italy.ORCID 0000-0002-0446-6436
Maurizio PolanoExperimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano, Istituto di Ricovero e Cura a Carattere Scientifico, 33081 Aviano, Italy.ORCID 0000-0002-6101-1382
Giuseppa ScandurraDepartment of Medical Oncology, A.O.E. Cannizzaro, 95126 Catania, Italy.ORCID 0000-0001-8025-581X
Angela PettinatoDepartment of Pathological Anatomy, A.O.E. Cannizzaro, 95126 Catania, Italy.ORCID 0009-0009-8156-9760
Corrado GiuntaLaboratory of Genomics, L.C. Laboratori Campisi, 96012 Avola, Italy.ORCID 0009-0009-2952-635X
Rosario IemmoloLaboratory of Genomics, L.C. Laboratori Campisi, 96012 Avola, Italy.ORCID 0000-0002-9297-8115
Paolo ScolloFaculty of Medicine and Surgery, "Kore" University, 94100 Enna, Italy.ORCID 0000-0001-6275-7488
Ettore D CapoluongoDepartment of Molecular Medicine and Medical Biotechnology, Federico II University, 80131 Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HRD (Homologous Recombination Deficiency) test is considered a genomic alteration useful for guiding therapeutic decisions in patients with ovarian cancer. Some commercial and in house alternative "academic" tests are available. Recent findings indicate that not all

Indexed as

BRCA1 ProteinBRCA2 ProteinCystadenocarcinoma, SerousHomologous RecombinationMutationOvarian NeoplasmsAdultAgedFemaleHumansMiddle AgedNeoplasm GradingBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCAHRDovarian cancer

Identifiers

PMID40427638
PMCPMC12110076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.